Prediction of recurrence risk in endometrial cancer with multimodal deep learning
Top Cited Papers
Open Access
- 24 May 2024
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 30 (7) , 1962-1973
Abstract
Predicting distant recurrence of endometrial cancer (EC) is crucial for personalized adjuvant treatment. The current gold standard of combined pathological and molecular profiling is costly, hampering implementation. Here we developed HECTOR (histopathology-based endometrial cancer tailored outcome risk), a multimodal deep learning prognostic model using hematoxylin and eosin-stained, whole-slide images and tumor stage as input, on 2,072 patients from eight EC cohorts including the PORTEC-1/-2/-3 randomized trials. HECTOR demonstrated C-indices in internal (n = 353) and two external (n = 160 andn = 151) test sets of 0.789, 0.828 and 0.815, respectively, outperforming the current gold standard, and identified patients with markedly different outcomes (10-year distant recurrence-free probabilities of 97.0%, 77.7% and 58.1% for HECTOR low-, intermediate- and high-risk groups, respectively, by Kaplan–Meier analysis). HECTOR also predicted adjuvant chemotherapy benefit better than current methods. Morphological and genomic feature extraction identified correlates of HECTOR risk groups, some with therapeutic potential. HECTOR improves on the current gold standard and may help delivery of personalized treatment in EC.Keywords
This publication has 71 references indexed in Scilit:
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Outcome of Endometrial Cancer Stage IIIA with Adnexa or Serosal Involvement OnlyObstetrics and Gynecology International, 2011
- On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival dataStatistics in Medicine, 2011
- Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer – Results from two randomised studiesEuropean Journal of Cancer, 2010
- Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trialThe Lancet, 2010
- Revised FIGO staging for carcinoma of the vulva, cervix, and endometriumInternational Journal of Gynecology & Obstetrics, 2009
- Surgically staged high-risk endometrial cancer: Randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapyGynecologic Oncology, 2008
- Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trialThe Lancet, 2000
- Assessment and comparison of prognostic classification schemes for survival dataStatistics in Medicine, 1999